Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat ...
Bio-Techne expands 3D stem cell and organoid culture portfolio with a fully defined synthetic alternative: Minneapolis Tuesday, February 3, 2026, 17:00 Hrs [IST] Bio-Techne Corpor ...
Calcium oxalate stones comprise greater than 70% of all kidney stones. In the current conceptual framework, the initial stone ...
Pluri, Inc. ('Pluri”, the 'Company”, 'we” or 'us”) (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary ...
The global amniotic products market is projected to grow at a CAGR of approximately 8%, reaching nearly USD 1 billion by 2031 ...
SCTIMST introduces CholeDerm, the world’s first animal-origin wound dressing, promoting faster healing with reduced scarring.
Global Scaffold Technology Market OverviewThe global scaffold technology market is poised for robust expansion, registering an estimated growth rate of around 13% over the next five years, driven by ...
Pluri, Inc. ("Pluri", the "Company", "we" or "us") (Nasdaq, TASE: PLUR), a biotechnology company leveraging its proprietary platform for cell-based solutions ...
A cryopreserved umbilical cord tissue connective tissue allograft, processed and distributed by Regenative Labs, was incorporated as part of the protocol. Umbilical cord tissue is a naturally ...
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results